p.96 抽出テキスト

outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315: 2673–82. https://doi.org/10.1001/jama.2016.7050 524. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, et al. Subgroup and perprotocol analyses from the hypertension in the very elderly trial. J Hypertens 2014;32: 1478–87; discussion 1487. https://doi.org/10.1097/hjh.0000000000000195 525. Jowett S, Kodabuckus S, Ford GA, Hobbs FDR, Lown M, Mant J, et al. Cost-effectiveness of antihypertensive deprescribing in primary care: a Markov modelling study using data from the OPTiMISE trial. Hypertension 2022;79:1122–31. https:// doi.org/10.1161/hypertensionaha.121.18726 526. Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, et al. Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial. Hypertension 2016;67:63–9. https://doi.org/10.1161/hypertensionaha. 115.06480 527. Chen T, Shao F, Chen K, Wang Y, Wu Z, Wang Y, et al. Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: a secondary analysis of randomized clinical trials. JAMA Intern Med 2022;182:660–7. https://doi.org/10.1001/jamainternmed.2022.1657 528. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study. Final results. Treatment of mild hypertension study research group. JAMA 1993;270:713–24. https://doi.org/10.1001/jama. 1993.03510060059034 529. Wu J, Kraja AT, Oberman A, Lewis C, Ellison R, Arnett D, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens 2005;18:935–42. https://doi.org/10.1016/j.amjhyper.2005.01.011 530. Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes A-C, Salam A, et al. Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart 2022;108:1281–9. https://doi. org/10.1136/heartjnl-2021-320171 531. Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S, et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine (Baltimore) 2016;95:e4071. https://doi.org/10.1097/md.0000000000004071 532. Morales-Salinas A, Kones R. Concerning the degradation of β-blocker use in the 2018 ESC/ESH hypertension guidelines. Eur Heart J 2019;40:2091. https://doi.org/10.1093/ eurheartj/ehz125 533. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545–53. https://doi.org/10.1016/s0140-6736(05)67573-3 534. Larochelle P, Tobe SW, Lacourcière Y. β-Blockers in hypertension: studies and meta-analyses over the years. Can J Cardiol 2014;30:S16–22. https://doi.org/10.1016/ j.cjca.2014.02.012 535. Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e116–35. https://doi.org/10.1161/hyp.0000000000000067 536. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev 2018;4:CD001841. https://doi.org/10.1002/14651858.CD001841.pub3 537. Johnston GD. Dose-response relationships with antihypertensive drugs. Pharmacol Ther 1992;55:53–93. https://doi.org/10.1016/0163-7258(92)90029-y 538. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. https://doi. org/10.1136/bmj.b1665 539. Messerli FH, Bangalore S, Schmieder RE. Wilder’s principle: pre-treatment value determines post-treatment response. Eur Heart J 2015;36:576–9. https://doi.org/10.1093/ eurheartj/ehu467 540. Lasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart 2011;97:1771–5. https://doi.org/10.1136/hrt.2010.221473 541. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014;32:2285–95. https://doi.org/10.1097/ hjh.0000000000000378 542. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525–33. https://doi. org/10.1016/s0140-6736(09)61340-4 543. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507–15. https://doi.org/10.1016/s0140-6736(13)60852-1 544. Vaduganathan M, Claggett BL, Juraschek SP, Solomon SD. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol 2020;5: 576–81. https://doi.org/10.1001/jamacardio.2019.6192 545. Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 2021;384: 1921–30. https://doi.org/10.1056/NEJMoa1901281 546. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, et al. Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation 2018;137:134–43. https://doi.org/10. 1161/circulationaha.117.030848 547. McEvoy JW, Daya N, Rahman F, Hoogeveen RC, Blumenthal RS, Shah AM, et al. Association of isolated diastolic hypertension as defined by the 2017 ACC/AHA blood pressure guideline with incident cardiovascular outcomes. JAMA 2020;323:329–38. https://doi.org/10.1001/jama.2019.21402 548. Jacobsen AP, Al Rifai M, Arps K, Whelton SP, Budoff MJ, Nasir K, et al. A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. Eur Heart J 2021;42:2119–29. https://doi.org/10.1093/eurheartj/ehab111 549. McEvoy JW, Yang WY, Thijs L, Zhang Z-Y, Melgarejo JD, Boggia J, et al. Isolated diastolic hypertension in the IDACO study: an age-stratified analysis using 24-hour ambulatory blood pressure measurements. Hypertension 2021;78:1222–31. https://doi.org/ 10.1161/hypertensionaha.121.17766 550. Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ 2021;372:n189. https://doi.org/10.1136/bmj.n189 551. Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM, et al. Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clin Sci (Lond) 2017;131:2671–85. https://doi.org/10.1042/cs20160407 552. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, et al. Plasma renin test–guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009;22:792–801. https://doi.org/10.1038/ajh.2009.63 553. Huang KY, Tseng PT, Wu YC, Tu Y-K, Stubbs B, Su K-P, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep 2021;11:452. https://doi.org/10.1038/s41598-020-79837-3 554. Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res 2021;7:00801-2020. https://doi.org/10.1183/23120541.00801-2020 555. Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 2008;17:1039–49. https://doi.org/10. 1002/pds.1656 556. Zhang Y, Song M, Chan AT, Meyerhardt JA, Willett WC, Giovannucci EL. Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study. Br J Cancer 2022;127:1974–82. https://doi.org/10. 1038/s41416-022-01975-4 557. Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis 2006;49:16–25. https://doi.org/10.1016/j.pcad.2006.06.002 558. Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability: clinical relevance and application. J Clin Hypertens (Greenwich) 2018;20:1133–7. https://doi.org/10. 1111/jch.13304 559. Schutte AE, Kollias A, Stergiou GS. Blood pressure and its variability: classic and novel measurement techniques. Nat Rev Cardiol 2022;19:643–54. https://doi.org/10.1038/ s41569-022-00690-0 560. Lauder L, Azizi M, Kirtane AJ, Böhm M, Mahfoud F. Device-based therapies for arterial hypertension. Nat Rev Cardiol 2020;17:614–28. https://doi.org/10.1038/ s41569-020-0364-1 561. Mahfoud F, Schlaich MP, Lobo MD. Device therapy of hypertension. Circ Res 2021;128: 1080–99. https://doi.org/10.1161/circresaha.121.318091 562. DiBona GF. Sympathetic nervous system and hypertension. Hypertension 2013;61: 556–60. https://doi.org/10.1161/hypertensionaha.111.00633 563. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010;298:R245–253. https://doi.org/ 10.1152/ajpregu.00647.2009 564. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet 2020;395:1444–51. https://doi.org/10.1016/s0140-6736(20)30554-7 565. Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, et al. The REDUCE HTN: REINFORCE: randomized, sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension. JACC Cardiovasc Interv 2020;13: 461–70. https://doi.org/10.1016/j.jcin.2019.10.061 566. Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:2346–55. https://doi.org/10.1016/s0140-6736(18) 30951-6 567. Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391:2335–45. https://doi.org/10.1016/s0140-6736(18)31082-1

ESC Guidelines                                                                                                                                                                                          4007

Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026